Research programme: cytokine inhibitors - Bioniz

Drug Profile

Research programme: cytokine inhibitors - Bioniz

Alternative Names: BJNZ132-2; BNZ 2; BNZ 3; BNZ132-3

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioniz
  • Class Peptides
  • Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 4 receptor antagonists; Interleukin 9 receptor antagonists; Interleukin receptor common gamma subunit inhibitors; Interleukin-21 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis
  • Research Autoimmune disorders; Coeliac disease

Most Recent Events

  • 13 Sep 2017 Pharmacodynamics data from a preclinical study in Coeliac disease released by (Company)
  • 13 Sep 2017 Bioniz Therapeutics plans a phase I trial of BNZ 2 for Coeliac disease in 2018
  • 08 Aug 2016 Early research in Autoimmune disorders in USA (unspecified route) (Bioniz Therapeutics pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top